INDP - Indaptus Therapeutics, Inc.
3.54
-0.070 -1.977%
Share volume: 79,709
Last Updated: 04-21-2026
Pharmaceutical Products/Pharmaceutical Preparations:
3.15%
PREVIOUS CLOSE
CHG
CHG%
$3.61
-0.07
-0.02%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | 12-31-2024 | 03-31-2025 | 09-30-2025 | 12-31-2025 | |
|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q3 2025 | Q4 2025 | |
| Report Date | 05-08-2024 | 08-12-2024 | 11-12-2024 | 03-13-2025 | 05-14-2025 | 11-12-2025 | 03-17-2026 | |
| Total revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Cost of revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Gross profit | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| nan% | nan% | nan% | nan% | nan% | ||||
| Operating expenses | 3.943 M | 4.109 M | 3.142 M | 4.172 M | 4.573 M | 2.648 M | 8.156 M | |
| Selling general and admin | 2.352 M | 2.395 M | 1.676 M | 1.692 M | 1.762 M | 1.131 M | 5.310 M | |
| Research and development | 1.591 M | 1.714 M | 1.466 M | 2.480 M | 2.811 M | 1.518 M | 2.845 M | |
| Total expenses | 3.943 M | 4.109 M | 3.142 M | 4.172 M | 4.573 M | 2.648 M | 8.156 M | |
| 4.20% | -23.53% | 32.77% | 9.61% | -42.08% | 207.94% | |||
| Operating income | -3.943 M | -4.109 M | -3.142 M | -4.172 M | -4.573 M | -2.648 M | -8.156 M | |
| Ebit | -3.807 M | -4.015 M | -3.069 M | -4.131 M | -4.532 M | -3.014 M | -8.196 M | |
| Pretax income | -3.807 M | -4.015 M | -3.069 M | -4.131 M | -4.532 M | -3.014 M | -8.196 M | |
| 5.48% | -23.57% | 34.60% | 9.72% | -33.50% | 171.91% | |||
| Income tax | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income basic | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income | -3.807 M | -4.015 M | -3.069 M | -4.131 M | -4.532 M | -2.975 M | -8.112 M | |
| -5.48% | 23.57% | -34.60% | -9.72% | 34.36% | -172.68% |